Metformin Inhibits Leptin-induced Growth and Migration of Glioblastoma Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Nov 20

PMID 23162655

Citations 21

Authors

Rita Ferla

Eva Haspinger

Eva Surmacz

Affiliations

Soon will be listed here.

Abstract

Metformin, a derivative of biguanide, is a first-line therapy for type 2 diabetes mellitus. Since the drug has been shown to significantly reduce the risk of various cancers and cancer mortality in diabetic patients, it is being considered as a potential anticancer therapeutic or preventive agent. In cellular models, metformin inhibits the growth of many types of cancer cells; however, its effects on glioblastoma multi-forme (GBM) are not well characterized. Here, we analyzed the effects of metformin on the growth and migration of LN18 and LN229 GBM cells cultured under basal conditions or exposed to leptin, a cytokine that has recently been implicated in GBM development. We found that 2-16 mM metformin reduced basal and leptin-stimulated growth of GBM cells in a dose-dependent manner. Furthermore, the drug significantly inhibited the migration of GBM cells. The action of metformin was mediated through the upregulation of its main signaling molecule, the adenosine monophosphate-activated protein kinase (AMPK), as well as through the downregulation of the signal transducer and activator of transcription 3 (STAT3) and the Akt/PKB serine/threonine protein kinase. In leptin-treated cells, the drug reversed the effects of the cytokine on the AMPK and STAT3 pathways, but modulated Akt activity in a cell-dependent manner. Our results suggest that metformin or similar AMPK-targeting agents with optimized blood-brain-barrier penetrability could be developed as potential treatments of GBM and could be used in conjunction with other target drugs such as leptin receptor antagonists.

Citing Articles

Metformin and its potential influence on cell fate decision between apoptosis and senescence in cancer, with a special emphasis on glioblastoma.

Hajimohammadebrahim-Ketabforoush M, Zali A, Shahmohammadi M, Hamidieh A Front Oncol. 2024; 14:1455492.

PMID: 39267853 PMC: 11390356. DOI: 10.3389/fonc.2024.1455492.

Discovery of a Novel Dual Targeting Peptide for Human Glioma: From Simulation to Acting as Targeting Ligand.

Sedghi Aminabad N, Saeedi Y, Adiban J, Nemati M, Shaterabadi D, Najafi F Adv Pharm Bull. 2024; 14(2):453-468.

PMID: 39206396 PMC: 11347739. DOI: 10.34172/apb.2024.033.

Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review.

Dixon S, Oconnor A, Brooks-Noreiga C, Clark M, Levy A, Castejon A Cancer Chemother Pharmacol. 2024; 94(1):1-23.

PMID: 38914751 DOI: 10.1007/s00280-024-04686-0.

Microglia and glioblastoma heterocellular interplay sustains tumour growth and proliferation as an off-target effect of radiotherapy.

Alberghina C, Torrisi F, DAprile S, Longhitano L, Giallongo S, Scandura G Cell Prolif. 2024; 57(6):e13606.

PMID: 38454614 PMC: 11150140. DOI: 10.1111/cpr.13606.

The Diagnostic and Therapeutic Role of Leptin and Its Receptor ObR in Glioblastoma Multiforme.

Kinfe T, Stadlbauer A, Bozhkov Y, Kremenevski N, Brandner S, Buchfelder M Cancers (Basel). 2020; 12(12).

PMID: 33316976 PMC: 7764087. DOI: 10.3390/cancers12123691.

References

Riolfi M, Ferla R, Del Valle L, Pina-Oviedo S, Scolaro L, Micciolo R . Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol. 2009; 20(2):481-9. PMC: 2864337. DOI: 10.1111/j.1750-3639.2009.00323.x. View

Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu A . Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells. Int J Mol Med. 2010; 26(5):713-21. DOI: 10.3892/ijmm_00000518. View

Ramachandran A, Snehalatha C . Diabetes prevention programs. Med Clin North Am. 2011; 95(2):353-72, viii. DOI: 10.1016/j.mcna.2010.11.006. View

Scolaro L, Cassone M, Kolaczynski J, Otvos Jr L, Surmacz E . Leptin-based therapeutics. Expert Rev Endocrinol Metab. 2019; 5(6):875-889. DOI: 10.1586/eem.10.61. View

Beckner M, Gobbel G, Abounader R, Burovic F, Agostino N, Laterra J . Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest. 2005; 85(12):1457-70. DOI: 10.1038/labinvest.3700355. View

Tang T, Lord J, Norman R, Yasmin E, Balen A . Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2009; (4):CD003053. DOI: 10.1002/14651858.CD003053.pub3. View

Guo D, Cloughesy T, Radu C, Mischel P . AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle. 2009; 9(2):211-2. PMC: 3180897. DOI: 10.4161/cc.9.2.10540. View

Guo D, Hildebrandt I, Prins R, Soto H, Mazzotta M, Dang J . The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009; 106(31):12932-7. PMC: 2714280. DOI: 10.1073/pnas.0906606106. View

Hardie D . AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond). 2008; 32 Suppl 4:S7-12. DOI: 10.1038/ijo.2008.116. View

10.

Eyal S, Hsiao P, Unadkat J . Drug interactions at the blood-brain barrier: fact or fantasy?. Pharmacol Ther. 2009; 123(1):80-104. PMC: 2751796. DOI: 10.1016/j.pharmthera.2009.03.017. View

11.

Alimova I, Liu B, Fan Z, Edgerton S, Dillon T, Lind S . Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8(6):909-15. DOI: 10.4161/cc.8.6.7933. View

12.

Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V . Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007; 64(10):1290-302. PMC: 11136022. DOI: 10.1007/s00018-007-7080-4. View

13.

Sonntag B, Gotte M, Wulfing P, Schuring A, Kiesel L, Greb R . Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril. 2005; 84 Suppl 2:1173-9. DOI: 10.1016/j.fertnstert.2005.04.043. View

14.

Anisimov V . Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2(11):760-74. PMC: 3006019. DOI: 10.18632/aging.100230. View

15.

Yeh W, Lu D, Lee M, Fu W . Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia. 2008; 57(4):454-64. DOI: 10.1002/glia.20773. View

16.

Gonzalez-Angulo A, Meric-Bernstam F . Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010; 16(6):1695-700. PMC: 2840206. DOI: 10.1158/1078-0432.CCR-09-1805. View

17.

de la Iglesia N, Puram S, Bonni A . STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med. 2009; 9(5):580-90. PMC: 2712135. DOI: 10.2174/156652409788488739. View

18.

Zakikhani M, Blouin M, Piura E, Pollak M . Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010; 123(1):271-9. DOI: 10.1007/s10549-010-0763-9. View

19.

Jalving M, Gietema J, Lefrandt J, de Jong S, Reyners A, Gans R . Metformin: taking away the candy for cancer?. Eur J Cancer. 2010; 46(13):2369-80. DOI: 10.1016/j.ejca.2010.06.012. View

20.

Garofalo C, Surmacz E . Leptin and cancer. J Cell Physiol. 2005; 207(1):12-22. DOI: 10.1002/jcp.20472. View